vantrelimab · Oncology · Anti-PD-L1 / TIGIT bispecific for first-line metastatic NSCLC with PD-L1 ≥ 50%.
5 objectives · 3 on track, 2 at risk
| Objective | Product | Owner | Status | Progress | Confidence |
|---|---|---|---|---|---|
| SO-VTX-01Establish vantrelimab as the preferred chemotherapy-free first-line option in PD-L1 ≥ 50% NSCLC among thoracic oncology KOLs in launch markets. | Vantrexa | PRDr. Priya Raman | On track | 68% | High |
| SO-VTX-02Close the post-progression sequencing evidence gap through a real-world cohort and expert consensus. | Vantrexa | NPDr. Nikolai Petrov | At risk | 41% | Medium |
| SO-VTX-03Ensure PD-L1 testing readiness so that ≥ 80% of eligible patients in launch markets have a result within 7 days of diagnosis. | Vantrexa | SLDr. Sophie Laurent | On track | 74% | Medium |
| SO-VTX-04Deliver a complete, approved scientific communication platform and medical-information response library before each country launch. | Vantrexa | DCDavid Chen | On track | 88% | High |
| SO-VTX-JP-01Achieve JSMO scientific presence and Tier 1 KOL coverage in Japan ahead of PMDA approval. | Vantrexa | KWDr. Kenji Watanabe | At risk | 52% | Medium |
Initiative status mix per product; mean initiative progress alongside.
Active
7 initiatives · 61% mean progress
Status order: Completed · In progress · Planned · Not started · At risk · Blocked. Colours follow the status label shown in each legend.
Top 8 topics by insight count (duplicates excluded). Trend compares the last 60 days with the prior 60 days.
| Theme | Insights | Mean priority | Critical / High | Open high-priority | Trend (60d) |
|---|---|---|---|---|---|
| PD-L1 testing turnaround | 6 | 67 | 67% | 4 | Rising 2 vs 1 |
| Brain-metastasis subgroup data | 5 | 63 | 40% | 1 | Rising 3 vs 0 |
| Elderly / ECOG 2 patients | 5 | 60 | 40% | 0 | Flat 0 vs 0 |
| Chemotherapy-free first line | 5 | 57 | 20% | 0 | Flat 1 vs 1 |
| Infusion-reaction management | 4 | 58 | 25% | 1 | Rising 2 vs 1 |
| Sequencing after progression | 3 | 71 | 67% | 1 | Falling 0 vs 1 |
| Duration of response | 3 | 55 | 0% | 0 | Flat 0 vs 0 |
| Comparator checkpoint monotherapy | 2 | 71 | 100% | 0 | Falling 0 vs 1 |
2 initiatives at risk or blocked · 1 overdue tasks and actions
| Type | Item | Owner | Due | Status | Linked record |
|---|---|---|---|---|---|
| Task | T-1002Decide on SEQUENCE-RW data-licensing terms | HODr. Helen Okafor | 12 Sept 2026 (3 days ago) | At risk | Decision · DEC-0007 |
| Initiative | INI-0107Japan Tier 1 KOL engagement and JSMO presence | KWDr. Kenji Watanabe | 20 Dec 2026 (in 96 days) | At risk | Objective · SO-VTX-JP-01 |
| Initiative | INI-0102Post-progression sequencing RWE cohort (SEQUENCE-RW) | NPDr. Nikolai Petrov | 30 Jun 2027 (in 288 days) | At risk | Objective · SO-VTX-02 |
Submitted and reviewed engagements, FY2026 to date.
By stakeholder tier
Mean quality rating (1–5)
Mean 3.2 across 113 rated engagements: 1★ 0 · 2★ 9 · 3★ 58 · 4★ 44 · 5★ 2
Unique stakeholders
57
114 engagements
Tier 1 covered (6 mo)
15 / 24
63%
In person / virtual / phone
53 / 25 / 36
22% virtual
With ≥ 1 insight
38
33%
SLA compliance (MET-041) · target 92% · monthly, global scope
Jan 93.1% · Feb 92.4% · Mar 91.8% · Apr 92% · May 91.2% · Jun 90.6% · Jul 89.9% · Aug 89.4% · Sep 90.2%
The trend line is global; the counts below follow the selected scope.
Inquiries YTD
341
Open
4
Overdue
0
Breached (closed)
80
Escalated / safety
3 / 3
7 active publications · 3 of 5 planned submissions to date are submitted or beyond
Delayed milestones (4)
| Publication | Milestone | Due | Status | Owner |
|---|---|---|---|---|
| PUB-0011Health-economic model of vantrelimab in PD-L1-high NSCLC from a German payer perspective | Statistical review | 01 Aug 2026 (45 days ago) | At risk | Dr. Nikolai Petrov |
| PUB-0011Health-economic model of vantrelimab in PD-L1-high NSCLC from a German payer perspective | Submission | 15 Aug 2026 (31 days ago) | At risk | Dr. Nikolai Petrov |
| PUB-0005Plain-language summary: VOYAGE-1 results for patients and carers | Compliance review | 25 Aug 2026 (21 days ago) | At risk | David Chen |
| PUB-0005Plain-language summary: VOYAGE-1 results for patients and carers | Submission | 01 Sept 2026 (14 days ago) | Planned | David Chen |
4 projects · 3 active · 1 active at high risk
Scientific review 1 · Contracting 1 · Active 1 · Analysis 1
By evidence gap
| Evidence gap | Projects | Active | Budget |
|---|---|---|---|
| Sequencing after progression on vantrelimab | 1 | 1 | $1.4M |
| Outcomes in brain-metastasis subgroup | 1 | 0 | $3.2M |
| Health-economic value in EU markets | 1 | 1 | $240k |
| Outcomes in elderly and ECOG 2 patients | 1 | 1 | $380k |
Weighted completion across scorecard dimensions. Grey dimensions carry no score; stale dimensions were last reviewed more than 30 days ago.
| Scorecard | Score | Dimensions (G / A / R / no data) | Warnings |
|---|---|---|---|
| Vantrexa — EU5 & Japan launch readiness (6-month scorecard)Six-month scorecard · target 01 Dec 2026 · Dr. Priya Raman | 83% | 10 Green5 Amber0 Red0 No data | 4% of weight is stale2 milestones at risk or blocked |
| Vantrexa — Japan country scorecardCountry scorecard · target 01 Feb 2027 · Dr. Kenji Watanabe | 53% | 2 Green4 Amber1 Red1 No data | 15% of weight has no data10% of weight is stale1 milestone at risk or blocked |
FY2026 · planned $8.4M · committed $7.3M · actual $5.1M (61% consumed) · 2 lines at overrun risk
| Product | Planned | Committed | Actual | Consumed | Lines at risk |
|---|---|---|---|---|---|
| Vantrexa | $8.4M | $7.3M | $5.1M | 61% | BL-006 (Agency), BL-008 (Travel) |
6 teams · 6 over-allocated
Over-allocated teams
3 decisions proposed or under review
Contract blocked since August; evidence gap is the top insight theme.
Recommendation: Accept with carve-outs · Impact: Unblocks EVP-0001; first data cut Feb 2027 · Approvers: Dr. Helen Okafor, Oliver Brandt
Tier 1 coverage 52% vs 60% target; PMDA approval expected Q4.
Recommendation: Expedite with recruiter · Impact: +$45k recruiter fee; coverage target achievable by January · Approvers: Dr. Helen Okafor
INS-0047 and 6 related insights from US centres.
Recommendation: Phase IV · Impact: $3.2M over 2 years · Approvers: Dr. Helen Okafor
Tenant-wide; not narrowed by product or region.
Open DQ issues
14
3 high · 7 medium · 4 low
Integrations degraded / failed
2
Veeva CRM (Degraded), Veeva Vault CTMS (Failed)
AI outputs pending review
3
INS-0061, INS-0060, RPT-Q3-EXEC
Metrics with DQ warnings
0
None
helixor-private-llm-2026.08 · generated 2026-09-15 06:00 UTC · scope: Vantrexa · All regions · unapproved narratives are never distributed
Human review required
Strategic objectives
3 of 5 objectives are on track; 2 are at risk or off track (SO-VTX-02, SO-VTX-JP-01). Mean progress is 65% against a 70% year-end target.
Sources:SO-VTX-02SO-VTX-JP-01MET-001
Initiatives at risk
2 initiatives are at risk or blocked: Post-progression sequencing RWE cohort (SEQUENCE-RW) (at risk); Japan Tier 1 KOL engagement and JSMO presence (at risk).
Escalated risks
2 risks are escalated to leadership. SEQUENCE-RW data-licensing negotiation fails, leaving the sequencing evidence gap open at EU launch. Japan Tier 1 KOL coverage below 60% at PMDA approval due to single-MSL capacity.
Insights needing action
3 Critical or High insights have not yet been routed to an owning function. The most frequent open theme is "Infusion-reaction management".
Publication milestones
4 publication milestones are past due: Statistical review (PUB-0011); Submission (PUB-0011); Compliance review (PUB-0005); Submission (PUB-0005).
Decisions needed
3 decisions require leadership attention: Accept data-partner secondary-use clause for SEQUENCE-RW; Expedite second Japan MSL hire; Route brain-metastasis evidence gap to Clinical Development as Phase IV concept.